All antibodies (Abs) with effector function are produced in mammalian cells, whereas bacterial production is restricted to smaller targeting fragments (scFv and Fab) without effector functions. In this project, we isolated different peptides that bind one of several Ab effector molecules. We have developed bacterial expression vectors for direct cloning of these peptides as fusions to scFv and Fab, and have obtained targeting fragments that also have the ability to bind Ab effector molecules. Some of these fusions (pepbodies) may also initiate Ab effector functions. We have also genetically inserted T-cell epitopes into Abs with specificity for antigen-presenting cell (APC) surface molecules to target the Ab-T-cell epitope fusions (Troybodies) to APCs. The approach is to exchange loops in Ig constant domains with single copies of well-defined T-cell epitopes. We have shown that a number of such T-cell epitopes are loaded on to MHC class II on APCs and are presented to specific T-cells. An increase in T-cell activation of up to four orders of magnitude is achieved compared with synthetic peptide. Our current goal is to identify all the loops in all Ig constant domains that may be loaded with T-cell epitopes to produce a multi-vaccine.
Skip Nav Destination
Article navigation
August 2002
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
August 01 2002
Troybodies and Pepbodies
E. Lunde;
E. Lunde
*Division of Molecular Cell Biology, Department of Biology, P.O. Box 1050, Blindern, N-0316 Oslo, Norway
Search for other works by this author on:
V. Lauvrak;
V. Lauvrak
*Division of Molecular Cell Biology, Department of Biology, P.O. Box 1050, Blindern, N-0316 Oslo, Norway
Search for other works by this author on:
I. B. Rasmussen;
I. B. Rasmussen
*Division of Molecular Cell Biology, Department of Biology, P.O. Box 1050, Blindern, N-0316 Oslo, Norway
Search for other works by this author on:
K. W. Schjetne;
K. W. Schjetne
†Institute of Immunology, The National Hospital, N-0027 Oslo, Norway
Search for other works by this author on:
K. M. Thompson;
K. M. Thompson
†Institute of Immunology, The National Hospital, N-0027 Oslo, Norway
Search for other works by this author on:
T. E. Michaelsen;
T. E. Michaelsen
‡Department of Vaccinology, National Institute of Public Health, N-0403 Oslo, Norway
Search for other works by this author on:
O. H. Brekke;
O. H. Brekke
§Affitech AS, Oslo Research Park, N-0349 Oslo, Norway
Search for other works by this author on:
L. M. Sollid;
L. M. Sollid
†Institute of Immunology, The National Hospital, N-0027 Oslo, Norway
Search for other works by this author on:
B. Bogen;
B. Bogen
†Institute of Immunology, The National Hospital, N-0027 Oslo, Norway
Search for other works by this author on:
I. Sandlie
I. Sandlie
1
*Division of Molecular Cell Biology, Department of Biology, P.O. Box 1050, Blindern, N-0316 Oslo, Norway
1To whom correspondence should be addressed (e-mail ingersa@bio.uio.no)
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 13 2002
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2002 Biochemical Society
2002
Biochem Soc Trans (2002) 30 (4): 500–506.
Article history
Received:
March 13 2002
Citation
E. Lunde, V. Lauvrak, I. B. Rasmussen, K. W. Schjetne, K. M. Thompson, T. E. Michaelsen, O. H. Brekke, L. M. Sollid, B. Bogen, I. Sandlie; Troybodies and Pepbodies. Biochem Soc Trans 1 August 2002; 30 (4): 500–506. doi: https://doi.org/10.1042/bst0300500
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.